OR estimates and p-values for case–control screening of 18 Breast Cancer Association Consortium SNPs
Control | % | Case | % | Adjusted OR | CI* | p>|z| | |
---|---|---|---|---|---|---|---|
Utilizing NPS as a continuous score | |||||||
All | 1057 | 100 | 1236 | 100 | 5.76×10−10 | ||
Only Caucasians | 904 | 85.5 | 788 | 63.8 | 3.47×10−10 | ||
Excluding Caucasian | 153 | 14.5 | 448 | 36.3 | 0.32 | ||
Number of subjects at risk indicated by NPS score above Threshold group | |||||||
All† | 13 | 1.2 | 26 | 2.1 | 2.56 | 1.26 to 5.19 | 0.009 |
Only Caucasian† | 12 | 1.3 | 25 | 3.2 | 3.02 | 1.45 to 6.29 | 0.003 |
Excluding Caucasian | Never | ≥2.5 | |||||
OR of top and bottom percentiles using middle quintile as reference | |||||||
All | |||||||
0–1% | 11 | 1.0 | 5 | 0.4 | 0.50 | 0.16 to 1.56 | 0.232 |
1–5% | 42 | 4.0 | 28 | 2.3 | 0.72 | 0.42 to 1.24 | 0.239 |
95–99% | 41 | 3.9 | 73 | 5.9 | 1.99 | 1.27 to 3.12 | 0.003 |
99–100% | 11 | 1.0 | 22 | 1.8 | 2.74 | 1.27 to 5.90 | 0.010 |
Only Caucasian | |||||||
0–1% | 10 | 1.1 | 3 | 0.4 | 0.48 | 0.13 to 1.81 | 0.278 |
1–5% | 36 | 4.0 | 19 | 2.4 | 0.80 | 0.44 to 1.48 | 0.482 |
95–99% | 36 | 4.0 | 51 | 6.5 | 2.00 | 1.22 to 3.26 | 0.006 |
99–100% | 10 | 1.1 | 22 | 2.8 | 3.20 | 1.45 to 7.08 | 0.004 |
*Adjusted for study centre and race/ethnicity.
†NPS≥2.1. NPS, normalised polygene score.